LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.